Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from AbbVie

Patients in England to be offered daily pill that can halve migraine frequency

Nice approves first oral treatment with Atogepant that can prevent chronic and episodic migraines

The Guardian - UK

Alvotech Aims To Break Open The World's Most Notorious Pharma Market

Alvotech's 2024 plans include several product launches around the world through various partners, but the forthcoming introduction of SIMLANDI® in the U.S. is in a market that is truly in the spotlight.

International Business Times

3 Passive Income Stocks To Scoop Up Now

These three stocks have earned the title of Dividend Kings by consistently increasing dividends for at least 50 years.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

3 Pharma Stocks Fueling Investor Enthusiasm

The pharmaceutical industry is expected to expand rapidly due to growing global healthcare needs and advancements in technology. Therefore, fundamentally strong pharma stocks Merck (MRK), AbbVie (ABBV), and GSK plc (GSK) might be ideal additions to your portfolio. Read on.

StockNews.com

4 Top Dividend Kings to Earn Passive Income

Dividend Kings are companies with a long history of paying and increasing shareholder dividends, which signals strong financial health for investors looking to build a steady stream of passive income.

Barchart

AbbVie (ABBV) Earnings Preview: Buy or Sell Opportunities

While AbbVie (ABBV) saw a decrease in net revenues and EPS in the last reported quarter, it raised its 2023 adjusted EPS guidance range. With the company gearing up to report fourth-quarter 2023 results tomorrow, is the stock worth buying today? Keep reading.

StockNews.com

A new test could save arthritis patients time, money and pain. But will it be used?

Stories of chronic pain, drug-hopping, and insurance meddling are all too common among patients with rheumatoid arthritis. Precision medicine offers new hope.

WEKU

Read news from The Economist, FT, and more,
with one subscription

Are These 3 Pharma Stocks Smart Buys for Bullish Investors?

The pharmaceutical industry's outlook looks promising, given robust healthcare spending worldwide and the rapid adoption of advanced digital technologies. Amid this, let’s find out if pharma stocks AbbVie (ABBV), Collegium Pharmaceutical (COLL), and Merck (MRK) are ideal buys now. Read on to know more….

StockNews.com

Stock market today: Asian shares are mostly higher ahead of a key US jobs report

Asian shares are mostly higher ahead of a U.S. jobs report after Wall Street rose Thursday to snap its first three-day losing streak since Halloween

The Independent UK

What it really takes to be a great place to work

There’s no one-size-fits-all model, but it can be done at virtually any organization.

Fortune

Analyzing December Profit Potential for the Top 4 Pharma Stocks

The global pharmaceutical market is witnessing robust growth, fueled by an escalating demand for healthcare services amid a burgeoning and aging population. Hence, fundamentally solid pharma stocks Novartis (NVS), Bristol-Myers Squibb (BMY), AbbVie (ABBV), and Taro Pharmaceutical (TARO) might be solid buys for gains this month. Read more.

StockNews.com

Broader Market Settles Higher on Improved Soft-Landing Prospects

What you need to know… The S&P 500 Index ($SPX ) (SPY ) Thursday closed up +0.38%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +1.47%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.25%. Stocks on Thursday settled mixed, with the Dow Jones...

Barchart

Stocks Mixed as Higher Bond Yields Weigh on Tech Stocks

What you need to know… The S&P 500 Index ($SPX ) (SPY ) today is down -0.07%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.84%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.77%. Stocks this morning are mixed, with the Dow Jones...

Barchart

3 Defensive Dividend Stocks to Protect Your Portfolio

Dividend-paying stocks are having a tough year, but there are still some top-rated income picks worth buying at current levels. Here's a look at three dividend stocks that can actually help defend your portfolio from market volatility.

Barchart

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

Can Pfizer (PFE) and AbbVie (ABBV) Cure Your Portfolio's Ailments?

The pharmaceutical industry is expected to thrive amid robust demand and technological advancements. Amid this, let’s analyze the fundamentals of AbbVie (ABBV) and Pfizer (PFE) to determine whether these stocks are worth buying now.

StockNews.com

Top 3 Pharma Stocks to Boost Your Portfolio

As the global population ages and faces the increasing toll of chronic diseases, the pharmaceutical industry is expected to step up to meet people’s healthcare needs. Against this backdrop, pharma companies like Novo Nordisk (NVO), AbbVie (ABBV), and Novartis (NVS) could boost your portfolio. Read on….

Barchart

Building Wealth with Spinoffs: How Adding These Gems Can Transform Your Portfolio

Spinoffs are value creating investment opportunities. You should be looking at them

Salon

Big Pharma’s playbook for expensive meds

Here are just a few of the many examples of drug pricing practices that have driven consumers to demand change

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

Are Pfizer (PFE) and AbbVie (ABBV) Good Value Buys for August?

The pharma industry is poised to witness long-term growth with the introduction of generic medicines and growing demand for personalized and targeted treatments. Hence, fundamentally strong pharma stock AbbVie (ABBV) might be worth buying. However, it might not be the right time to invest in Pfizer (PFE). Keep reading.

Zenger

AbbVie’s Underperformance, Deere’s Catch-Up Potential, And Pioneer’s Earnings Awaited

AbbVie's underperformance, Jim Lebenthal sees Deere as a catch-up trade, and analysts await Pioneer's earnings report.

Barchart

3 High-Paying Unusually Active Put Options to Sell for Extra Cash This Weekend

It’s the last day of the trading week, so investors are looking for extra spending money for the weekend ahead. Here are three unusually active put options to sell: high-paying and worthwhile long-term holds.

Tribune News Service

Humira, the world’s top-selling drug, faces an upcoming test from low cost alternatives

If you’re one of the millions of Americans taking the prescription medication Humira, get ready to add the word biosimilars to your conversations with your doctor.

The Independent UK

Cheaper competition for Humira is hitting the market, but savings will depend on your insurance

Patients who take the autoimmune disease treatment Humira may see some price relief when several lower-cost, biosimilar versions of the AbbVie drug reach the U.S. market in July

Barchart

3 Dependable Dividend Stocks to Consider in the Second Half Of 2023

These 3 dividend stocks have uninterruptedly paid and raised their dividends for years. Further, these stocks have outperformed the broader markets, and Wall Street analysts have a favorable outlook on them.

Kiplinger

Best Retirement Stocks for Income Investors in the Golden Years

The best retirement stocks ideally have attractive dividends that can be sustained. This can lead to steady income and long-term value for retirees.

1 … 6 7 8 9

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.